AdAlta Limited (ASX:1AD)

Market Cap	10.20M +7.6%
Revenue (ttm)	608.07K -37.5%
Net Income	-4.36M
EPS	-0.00
Shares Out	2.55B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,338,982
Average Volume	4,179,126
Open	0.0040
Previous Close	0.0040
Day's Range	0.0040 - 0.0040
52-Week Range	0.0020 - 0.0080
Beta	0.03
RSI	47.62
Earnings Date	May 20, 2026

About AdAlta

AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. It has discovered WD-34 for the multiple malaria species, Babesia, and Toxoplasma in collaboration with La Trobe Univers...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 1
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: 1AD

Financial Performance

In fiscal year 2025, AdAlta's revenue was 677,010, a decrease of -61.04% compared to the previous year's 1.74 million. Losses were -4.50 million, -16.33% less than in 2024.